TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to provide an update on the research and development initiatives of its psychedelic product programs and upcoming milestones for 2021.
Committee for medicinal products for human use (CHMP)
A Federal Court judge has ordered Health Canada to release reams of pharmaceutical clinical trial data on five medications to an American researcher, undercutting the federal government's attempts to keep the information confidential.
In collaboration with PerkinElmer, NDF aims to use sequencing and metabolomics to study 100 patient samples. The partners will also collect their findings into a database to help with patient recruitment for clinical trials.
Hyderabad-based Hetero Healthcare Limited, the first pharma company in India to launch anti-H1N1 drug oseltamivir in retail market under the brand name Fluvir, will be supplying 14,000 bottles of oseltamivir syrup to replenish the stocks in retail trade in the state of Gujarat to avert any stock out in the near future. There are around 37,000 retail and wholesale licensees in the state of Gujarat for which consistent supplies are required.
Swine Flu in Delhi: Most-Affected State, Country Death Toll Reaches 1000
CDC Urges Widespread Use of Antiviral Drugs to Combat Flu
BioCryst Hits Trifecta For Flu, Ebola, and Hereditary Angioedema